LG Chem said Wednesday that it has launched Zemiro, a combination drug for treating diabetes and dyslipidemia.
Zemiro is a new drug combining DPP-4 inhibitor-based diabetes drug Zemiglo and dyslipidemia treatment ingredient Rosuvastatin. It is the first of its kind to treat such diseases in Korea.
The drug comes amid the rising need for a treatment that covers both diabetes and dyslipidemia. Nine out of 10 diabetic patients are diagnosed with dyslipidemia, according to the Guideline for the Treatment of Dyslipidemia published by the Korean Society of Lipidology & Atherosclerosis 한국지질동맥경화학회.
The drug is efficient in that patients only need to take one pill of Zemiro to treat their conditions compared to the multiple medications that they previously took. It is also expected to lift the financial burden of patients due to its low cost. If patients, who took both drugs, replace their treatment with Zemiro, it can reduce more than 25 percent of their insured price.
“LG Chem LG화학 plans to become a leading force in the diabetes treatment market by using LG’s flagship products such as Zemiro and Zemimet SR,” said Son Ji-woong 손지웅, head of LG Chem’s Life Science Business Division.
The company plans to open a national symposium starting in Daegu to promote their new drug in November, planning to launch the sales of Zemiro in the fourth quarter of this year.
<© Korea Biomedical Review, All rights reserved.>